文献速递糖尿病

2型糖尿病患者降糖药物处方与COVID-19死亡风险:英格兰全国观察性研究

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-03-30

该全国观察性队列研究纳入英格兰2 851 465例2型糖尿病患者,分析2020年2月16日至8月31日期间降糖药物处方与COVID-19相关死亡的关系。作者认为差异较小且可能受适应证混杂影响,无明确指征改变处方。

要点

  • 多数其他降糖药风险比接近1,差异可能源于适应证混杂。

核心结论

  • 部分降糖药物处方与COVID-19相关死亡存在关联,但风险差异小,可能为适应证混杂所致。
  • 在COVID-19大流行背景下,无明确指征改变2型糖尿病患者的降糖药物处方。

研究设计与样本

  • 全国观察性队列研究,使用英格兰国家糖尿病审计数据,纳入自2003年起在全科诊所注册的2型糖尿病患者。
  • 采用Cox回归估计COVID-19相关死亡的风险比(HR),并用倾向评分调整人口学、社会经济和临床因素。

临床怎么用

  • 临床不应仅基于COVID-19风险改变2型糖尿病患者的降糖药物处方。
  • 处方选择仍应基于患者个体化降糖需求及药物适应证。

局限性

  • 研究为观察性设计,风险差异小且可能受适应证混杂影响,不同药物用于疾病不同阶段。
  • 无法完全排除未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with type 2 diabetes, hyperglycaemia is an independent risk factor for COVID-19-related mortality. Associations between pre-infection prescription for glucose-lowering drugs and COVID-19-related mortality in people with type 2 diabetes have been postulated but only investigated in small studies and limited to a few agents. We investigated whether there are associations between prescription of different classes of glucose-lowering drugs and risk of COVID-19-related mortality in people with type 2 diabetes. METHODS: This was a nationwide observational cohort study done with data from the National Diabetes Audit for people with type 2 diabetes and registered with a general practice in England since 2003. Cox regression was used to estimate the hazard ratio (HR) of COVID-19-related mortality in people prescribed each class of glucose-lowering drug, with covariate adjustment with a propensity score to address confounding by demographic, socioeconomic, and clinical factors. FINDINGS: Among the 2 851 465 people with type 2 diabetes included in our analyses, 13 479 (0·5%) COVID-19-related deaths occurred during the study period (Feb 16 to Aug 31, 2020), corresponding to a rate of 8·9 per 1000 person-years (95% CI 8·7-9·0). The adjusted HR associated with recorded versus no recorded prescription was 0·77 (95% CI 0·73-0·81) for metformin and 1·42 (1·35-1·49) for insulin. Adjusted HRs for prescription of other individual classes of glucose-lowering treatment were as follows: 0·75 (0·48-1·17) for meglitinides, 0·82 (0·74-0·91) for SGLT2 inhibitors, 0·94 (0·82-1·07) for thiazolidinediones, 0·94 (0·89-0·99) for sulfonylureas, 0·94 (0·83-1·07) for GLP-1 receptor agonists, 1·07 (1·01-1·13) for DPP-4 inhibitors, and 1·26 (0·76-2·09) for α-glucosidase inhibitors. INTERPRETATION: Our results provide evidence of associations between prescription of some glucose-lowering drugs and COVID-19-related mortality, although the differences in risk are small and these findings are likely to be due to confounding by indication, in view of the use of different drug classes at different stages of type 2 diabetes disease progression. In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021. PMID: 33798464. doi:10.1016/S2213-8587(21)00050-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。